Molecular docking and antimalarial evaluation of novel N-(4-aminobenzoyl)-l-glutamic acid conjugated 1,3,5-triazine derivatives as Pf-DHFR inhibitors
作者:Nayana Adhikari、Ayesha Aktar Khanam Choudhury、Anshul Shakya、Surajit Kumar Ghosh、Saurav Jyoti Patgiri、Udaya Pratap Singh、Hans Raj Bhat
DOI:10.1007/s13205-022-03400-2
日期:2022.12
Malaria has been a source of concern for humans for millennia; therefore in the present study we have utilized in-silico approach to generate diverse anti-malarial hit. Towards this, Molinspiration cheminformatics and Biovia Discovery Studio (DS) 2020 were used to conduct molecular modelling studies on 120 designed compounds. Furthermore, the TOPKAT module was used to evaluate the toxicity of the screened compounds. The CDOCKER docking technology was used to investigate protein–ligand docking against the Pf-DHFR-TS protein (PDB ID: 1J3I and 1J3K). These compounds were synthesized using a conventional and microwave-assisted nucleophilic substitution reaction, and they were characterized using a variety of physicochemical and spectroscopic methods. Among the ten compounds tested, Df3 had the highest antimalarial activity against the chloroquine-resistant (Dd2) strain, with an IC50 value of 9.54 μg mL−1 and further demonstrate, molecular dynamics (MD) simulation studies and estimation of MM-PBSA-based free binding energies of docked complexes with 1J3I and 1J3K were carried out. The discovery of a novel class of Pf-DHFR inhibitors can be accomplished using this hybrid scaffold.
疟疾困扰人类已有数千年之久,因此,在本次研究中,我们利用计算机模拟方法来生成不同的抗疟疾化合物。为此,我们使用Molinspiration化学信息学和Biovia Discovery Studio (DS) 2020对120种设计化合物进行了分子建模研究。此外,我们还使用TOPKAT模块来评估筛选化合物的毒性。CDOCKER对接技术用于研究Pf-DHFR-TS蛋白(PDB ID:1J3I和1J3K)的蛋白质-配体对接。这些化合物是通过传统的和微波辅助的亲核取代反应合成的,并使用各种物理化学和光谱方法进行了表征。在测试的十种化合物中,Df3对氯喹耐药(Dd2)菌株的抗疟活性最高,IC50值为9.54 μg mL−1,并进一步进行了分子动力学(MD)模拟研究,以及对接复合物与1J3I和1J3K的MM-PBSA自由结合能的估计。使用这种混合支架可以发现一类新的Pf-DHFR抑制剂。